Tecnovatica (TEC) Stock Overview
Engages in the building and development of an integrated ecosystem of health services using modern genetics and imaging diagnostics in Poland, the European Union and global markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TEC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Tecnovatica S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.32 |
| 52 Week High | zł1.19 |
| 52 Week Low | zł0.23 |
| Beta | -0.22 |
| 1 Month Change | 3.95% |
| 3 Month Change | -4.24% |
| 1 Year Change | -22.93% |
| 3 Year Change | -3.66% |
| 5 Year Change | -77.43% |
| Change since IPO | -97.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| TEC | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 3.9% | -0.6% | 2.3% |
| 1Y | -22.9% | -0.6% | 38.7% |
Return vs Industry: TEC underperformed the Polish Biotechs industry which returned -1.3% over the past year.
Return vs Market: TEC underperformed the Polish Market which returned 37.4% over the past year.
Price Volatility
| TEC volatility | |
|---|---|
| TEC Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in PL Market | 10.5% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: TEC's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: TEC's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Michal Marczuk | www.tecnovatica.pl |
Tecnovatica S.A. engages in the building and development of an integrated ecosystem of health services using modern genetics and imaging diagnostics in Poland, the European Union and global markets. Its areas of activity are NIPT prenatal diagnostics, genetic cancer diagnostics, artificial intelligence in diagnostics, telemedicine and mobile applications, medical marijuana and supportive therapies, and translational medicine and scientific cooperation. The company was formerly known as Vinci Gen S.A. and changed its name to Tecnovatica S.A. in January 2026.
Tecnovatica S.A. Fundamentals Summary
| TEC fundamental statistics | |
|---|---|
| Market cap | zł3.40m |
| Earnings (TTM) | zł69.77k |
| Revenue (TTM) | zł52.62k |
Is TEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEC income statement (TTM) | |
|---|---|
| Revenue | zł52.62k |
| Cost of Revenue | zł0 |
| Gross Profit | zł52.62k |
| Other Expenses | -zł17.15k |
| Earnings | zł69.77k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0065 |
| Gross Margin | 100.00% |
| Net Profit Margin | 132.60% |
| Debt/Equity Ratio | 26.5% |
How did TEC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 12:19 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tecnovatica S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.